🚨 #ESMO26 Presidential 2 | HARMONi-GI1 Ph3

Ivonescimab (PD-1/VEGF bispecific) + GemCis vs durvalumab + GemCis as 1L in advanced BTC (n=682; China)
✅ mOS: 14.9 vs 12.1 mo (HR 0.75)
✅ mPFS: 8.4 vs 5.8 mo (HR 0.61)
✅ ORR: 53.8% vs 32.5%
❌new signals
#GIOnc #BTC #OncTwitter